Daejeon, South Korea

Duk Soon Hwang



 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2019-2020

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Duk Soon Hwang

Introduction

Duk Soon Hwang is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of peptides with therapeutic applications. With a total of 2 patents, Hwang's work focuses on addressing critical health issues, including Alzheimer's disease and cancer.

Latest Patents

Hwang's latest patents include a peptide that suppresses the binding of beta-amyloid and an anti-cancer peptide. The first patent provides a peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2, or a pharmaceutically acceptable salt thereof. This invention can inhibit the entry of beta-amyloid into the brain, offering a promising approach to mitigate the effects of Alzheimer's disease. The second patent describes a peptide that can effectively prevent or treat cancer, showcasing Hwang's commitment to advancing medical science.

Career Highlights

Duk Soon Hwang is currently associated with Ensol Biosciences Inc., where he continues to innovate and develop new therapeutic solutions. His work has garnered attention for its potential impact on public health, particularly in the areas of neurodegenerative diseases and oncology.

Collaborations

Hwang collaborates with notable colleagues, including Hae Jin Kim and Eun Joung Moon. These partnerships enhance the research and development efforts at Ensol Biosciences Inc., fostering an environment of innovation and discovery.

Conclusion

Duk Soon Hwang's contributions to biotechnology through his innovative patents highlight his dedication to improving health outcomes. His work in developing peptides for critical health challenges positions him as a key figure in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…